Having to take Ozempic or other weight loss drugs can be a real pain in the ass, with users often having to jab themselves ...

A new drug from California-based pharma company Amgen, which has concluded a phase II trial, shows promise as a powerful ...

Amgen’s monthly obesity candidate led to substantial weight loss but a high rate of side effects and discontinuations in a ...

The once-monthly drug is still under study but could provide added convenience and another option for patients.

US biotech major Amgen, a late comer to the growing obesity treatment space, released new data showing that its MariTide ...

MariTide is designed to combine the effects of glucagon-like peptide-1 (GLP-1) receptor activation with glucose-dependent ...

Amgen aims to challenge obesity drug leaders with MariTide, a potential monthly treatment now in late-stage trials.

In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...

In a Phase II trial, Amgen’s investigational therapy MariTide (maridebart cafraglutide) delivered significant, sustained ...

At the diabetes conference, Eli Lilly presented results of a phase 1 trial of its experimental drug, eloralintide. Unlike GLP ...

Drugs such as Ozempic (a brand name for semaglutide) are showing promise for weight loss. Another medication in the same ...

Trial finds weight loss drug taken monthly helps people lose 20% of body weight – but adverse GI events were ‘common’ - The ...